Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29812175 | 1.00 | CA9 (0.44) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL18341938 | 0.86 | CA9 (0.45) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL2929573 | 0.80 | CES2 (0.36) | CA9CA12CA1ERN1CES2 | |
| Phosphine SCHEMBL28854043 | 0.77 | CES2 (0.35) | CA9CA12CA1ERN1CES2 | |
| SCHEMBL25085814 | 0.75 | TSHR (0.41) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL30994085 | 0.75 | PTGS1 (0.38) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL30412164 | 0.75 | CA9 (0.36) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL31644952 | 0.75 | SELL (0.52) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL23899974 | 0.75 | CA9 (0.36) | CA9CA3CA6CA5ACA14 | |
| SCHEMBL30890596 | 0.75 | CYP3A4 (0.35) | CA9CA3CA6CA5ACA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166612-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4294523-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-Biotix Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022178228-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2008114123-A1 | SPIRO BENZIMIDAZOLE DERIVATIVES AS ACID PUMP INHIBITORS | RAQUALIA PHARMA INC. (JP) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166612-A1 | ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AGXT, AADAC, AGPAT2 | CA9 1100/4885CA3 4324/4885CA6 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.